Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06295770

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Led by Mayo Clinic · Updated on 2026-04-13

20

Participants Needed

1

Research Sites

127 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).

CONDITIONS

Official Title

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Biopsy-confirmed fibrillary glomerulonephritis
  • Proteinuria greater than 1.0 g/24 hours before starting immunosuppressive therapy
  • Estimated glomerular filtration rate (eGFR) of at least 20 ml/min/BSA
Not Eligible

You will not qualify if you...

  • Secondary fibrillary glomerulonephritis caused by monoclonal gammopathy, autoimmune disease, or cancer
  • Presence of other kidney diseases on biopsy, such as diabetic nephropathy
  • Positive test for hepatitis B, hepatitis C, or HIV
  • Pregnant or breastfeeding
  • Active infection at the time of screening
  • History of kidney transplant
  • Anemia with hemoglobin less than 8.0 g/dL
  • Low platelet count below 100,000
  • Any other condition or abnormal test that increases risk or affects study results
  • Use of cyclophosphamide within the past 6 months
  • Use of ACTH or mycophenolate mofetil within the past 30 days
  • Use of prednisone above 10 mg/day in the past 15 days
  • Previous rituximab treatment with CD20 count below 5 cells/microliter at enrollment
  • For women who are not postmenopausal or surgically sterile: agreement to use two effective contraception methods during treatment and for 18 months after
  • For men: agreement to use two effective contraception methods during treatment and for 6 months after

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mayo Clinic

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

N

Nicholas Geroux

CONTACT

C

Corbyn Bendtsen

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here